Acino ? Delivering Health

More documents

Recommendations

Info

Successful in emerging markets in BtC How to escape price pressure in BtB Ruud van Anraat, CCO Acino Group December 5, 2012 Aesch Acino Holding Ltd. Erlenstrasse 1 | CH-4058 Basle | www.acino-pharma.com Phone +41 61 338 60 00 | Fax +41 61 338 60 80
Entering emerging markets / “Swissness“ Many markets, especially in the Acino target regions, are still dependent on imported pharmaceuticals and/or acceptance of locally produced products is low – High medical need for valued-added products/niche specialities with high quality background from CH/EU sources Acino’s target markets have a low acceptance of products out of India/China vs. high valued Swiss/EU origin – Market research results show highest perception of Swiss origin products in general of pharmaceuticals in particular in almost all target markets. EU origin products (preferably “Made in Germany”) are highly valued as well High “Swiss” pharmaceutical brand awareness heritage – Mepha has created a high value “Swiss” brand equity that can be more easily transferred to “Acino Switzerland” brand due to a high overlap of shared values 35
Page 1 and 2: Acino - Delivering Health Investor
Page 3 and 4: Acino - drug delivery specialist, m
Page 5 and 6: Acino’s growth drivers Fully expl
Page 7 and 8: Technology platform Oral modified r
Page 9 and 10: Oral modified release forms MUPS (M
Page 11 and 12: Technology platform Oral dispersibl
Page 13 and 14: Technology platform Transdermal sys
Page 15 and 16: Transdermal systems Why transdermal
Page 17 and 18: Technology platform Extended releas
Page 19 and 20: Extended release parenterals Advant
Page 21 and 22: Development projects Ferrous sulfat
Page 23 and 24: Development projects Rivastigmine T
Page 25 and 26: Development projects Goserelin & le
Page 27 and 28: Development projects Goserelin 1 &
Page 29 and 30: Development projects Leuprorelin 1
Page 31 and 32: Acino’s development pipeline Stat
Page 33: Acino - Delivering Health Thank you
Page 37 and 38: Acino Switzerland 2009 BtC markets
Page 43 and 44: Opportunities Products with added v
Page 45 and 46: Acino Switzerland: Product Portfoli
Page 47 and 48: Acino portfolio Roll-out in new ter
Page 49 and 50: Criteria for selecting products for
Page 51 and 52: Acino’s business model (example)
Page 53 and 54: Optimized BtB Concept - Geographica
Page 55 and 56: Technical Marketing and Operations:
Page 57 and 58: Acino’s production importance Tec
Page 59 and 60: Production Technologies: Value for
Page 61 and 62: Pellets Innovative technologies for
Page 63 and 64: Pellet Projects High volume project
Page 65 and 66: Granulates Hot melt granulation Sp
Page 67 and 68: Manufacturing Process 67
Page 70 and 71: Implants Implant manufacturing capa
Page 72 and 73: Opportunity: High Quality Service S
Page 74 and 75: Summary Focus on niche technologies
Page 76 and 77: Competitive advantage factor: HighT
Page 78 and 79: Micro Error Tracking System (METS)
Page 80 and 81: Strategy to cope with declining mar
Page 82 and 83: Financials Robert Schmid, Head of I
Page 84 and 85:
Promising potential areas of synerg
Page 86 and 87:
Reduced currency exposure Mepha / C
Page 88 and 89:
Summary and strategy Peter Burema,
Page 90 and 91:
Acino’s growth drivers Fully expl
Page 92 and 93:
Geographic break-down of revenue DE
Page 94:
Acino - Delivering Health Thank you
show all

Acino ? Delivering Health

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?